Silo Pharma (NASDAQ:SILO) has entered into an agreement with WuXi AppTec for a preclinical small animal study of SPU-16, a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS).
Silo Pharma is advancing the development of the SPU-16 liposomal homing peptide through a commercial evaluation license and option agreement with the University of Maryland, Baltimore.
“We are excited to launch this new study of our novel CNS homing peptide under the management of WuXi AppTec, one of the largest CROs in Asia and globally,” Eric Weisblum, CEO of Silo, said in a statement. “Designed to cross the blood-brain barrier and target damaged tissue and inflammation, SPU-16 has been shown to enhance the therapeutic effect of current and future therapeutics while decreasing the toxicity of the drugs. While we are currently investigating the peptide for MS, it could provide similar benefits for multiple neuroinflammatory pathologies.”
MS is a potentially disabling inflammatory demyelinating disease of the brain and spinal cord, currently affecting 2.9 million patients worldwide. The global MS market size is projected to grow at a CAGR of 7.9% from $21.2 billion in 2024 to $38.9 billion by 2032, according to Fortune Business Insights.
